Piotr Pawłucki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Piotr Pawłucki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anna Maciak
The Military Clinical Hospital with Polyclinic in Krakow, Wrocławska 1/3 Street, 30-901
5 shared publications - Michał Sekuła
Doctoral School, Medical University of Lublin, Lublin, Poland.
5 shared publications - Paulina Cuper
Brothers Hospitallers of Saint John of God Hospital in Cracow; Trynitarska 11 Street, 31-061 Kraków, Poland
4 shared publications - Błażej Dziurowicz
Lesser Poland Orthopedic and Rehabilitation Hospital, Modrzewiowa 22 Av., 30-224 Kraków, Poland
2 shared publications - Ewelina Andrasz
The Rzeszów Bar Association, Litewska 4/8 Street, 35-302 Rzeszów, Poland
2 shared publications - Aleksandra Zimna
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Lublinie, Grenadierów 3, 20-331 Lublin
1 shared publication
Latest Publications
- Open Access
- 28 July 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 19, 53183
Complex minoxidil and platelet-rich plasma therapy effectiveness and its impact on physical performance
Background Minoxidil and platelet-rich plasma (PRP) are proven treatments for androgenetic alopecia, however their combined therapy is not as researched. Research materials and methods Materials used for our research consist of published papers that pertain to both minoxidil and platelet-rich plasma therapies. More comprehensive papers, such as those including other substances were also included although results about other substances were not included, we simply discarded them. Each of the found and chosen articles were added and processed by various formulas which aim were to calculate efficacy of combined therapy while minimizing the errors and biases that could prop up in the source papers. Overall goal was to consolidate knowledge of the efficacy of combined therapy of minoxidil and platelet-rich plasma with emphasis on effect that could affect the physical performance. Results All trials have shown statistically significant improvement when compared to minoxidil monotherapy. Compared to PRP monotherapy results had been superior although not always in statistically significant manner. No trials have shown additional, adverse interactions, side effects or impacts on physical performance beyond those expected from the monotherapies, proving combined is as safe as monotherapies. Conclusion Combined therapy is proven to yield better results, while remaining a safe and cost-effective method. It doesn’t impact physical performance in any way if taken correctly. Still higher quantity of research is welcome to make those finding more stable and in order to better assess the positive effect of combing titular substances.
- 28 July 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 19, 53183
Open AccessComplex minoxidil and platelet-rich plasma therapy effectiveness and its impact on physical performance
Background Minoxidil and platelet-rich plasma (PRP) are proven treatments for androgenetic alopecia, however their combined therapy is not as researched. Research materials and methods Materials used for our research consist of published papers that pertain to both minoxidil and platelet-rich plasma therapies. More comprehensive papers, such as those including other substances were also included although results about other substances were not included, we simply discarded them. Each of the found and chosen articles were added and processed by various formulas which aim were to calculate efficacy of combined therapy while minimizing the errors and biases that could prop up in the source papers. Overall goal was to consolidate knowledge of the efficacy of combined therapy of minoxidil and platelet-rich plasma with emphasis on effect that could affect the physical performance. Results All trials have shown statistically significant improvement when compared to minoxidil monotherapy. Compared to PRP monotherapy results had been superior although not always in statistically significant manner. No trials have shown additional, adverse interactions, side effects or impacts on physical performance beyond those expected from the monotherapies, proving combined is as safe as monotherapies. Conclusion Combined therapy is proven to yield better results, while remaining a safe and cost-effective method. It doesn’t impact physical performance in any way if taken correctly. Still higher quantity of research is welcome to make those finding more stable and in order to better assess the positive effect of combing titular substances.
- Open Access
- 19 August 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 45 (1) , 284-298
Effect of polycystic ovary syndrome on increased risk of cardiovascular disease
Introduction and purpose: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women. It is a very complex disease in which hormonal disorders result in a number of metabolic dysfunctions and malfunctioning of the ovaries. This can lead to infertility, miscarriage and an increased risk of endometrial cancer. The aim of our work is to draw attention to the influence of PCOS on increased cardiovascular risk. Brief description of the state of knowledge: The occurrence of PCOS, especially uncontrolled pharmacologically and non-pharmacologically, may be associated with an increased cardiovascular risk. The literature describes a higher incidence of dyslipidemia, carbohydrate metabolism disorders, obesity, hypertension, chronic inflammation and oxidative stress. As a consequence, it can lead to the development of metabolic syndrome. All these factors negatively affect the risk of developing cardiovascular disease. To prevent this, it is necessary to use appropriate pharmacological and non-pharmacological methods in women diagnosed with PCOS. Conclusion: The mechanism of PCOS is complex and its development is influenced by genetic, endocrine, metabolic and environmental factors. The lack of proper diagnosis and the lack of treatment of PCOS is associated with numerous metabolic complications and an increased risk of cardiovascular diseases. Due to the poorly understood pathomechanism of this disease, further long-term studies are needed to help diagnose and treat PCOS.
- 19 August 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 45 (1) , 284-298
Open AccessEffect of polycystic ovary syndrome on increased risk of cardiovascular disease
Introduction and purpose: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women. It is a very complex disease in which hormonal disorders result in a number of metabolic dysfunctions and malfunctioning of the ovaries. This can lead to infertility, miscarriage and an increased risk of endometrial cancer. The aim of our work is to draw attention to the influence of PCOS on increased cardiovascular risk. Brief description of the state of knowledge: The occurrence of PCOS, especially uncontrolled pharmacologically and non-pharmacologically, may be associated with an increased cardiovascular risk. The literature describes a higher incidence of dyslipidemia, carbohydrate metabolism disorders, obesity, hypertension, chronic inflammation and oxidative stress. As a consequence, it can lead to the development of metabolic syndrome. All these factors negatively affect the risk of developing cardiovascular disease. To prevent this, it is necessary to use appropriate pharmacological and non-pharmacological methods in women diagnosed with PCOS. Conclusion: The mechanism of PCOS is complex and its development is influenced by genetic, endocrine, metabolic and environmental factors. The lack of proper diagnosis and the lack of treatment of PCOS is associated with numerous metabolic complications and an increased risk of cardiovascular diseases. Due to the poorly understood pathomechanism of this disease, further long-term studies are needed to help diagnose and treat PCOS.
- Open Access
- 19 August 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 45 (1) , 269-283
Will the use of anabolic androgenic steroids become a significant cardiovascular risk factor in the future?
Introduction and purpose: Cardiovascular diseases are the leading cause of mortality in many European countries. Major modifiable risk factors include dyslipidemia, hypertension, smoking and diabetes. The aim of our study is to draw attention to the possible impact of the use of anabolic androgenic steroids on increased cardiovascular risk. Brief description of the state of knowledge: Currently, an increasing proportion of the population uses anabolic-androgenic steroids (AAS). This situation applies not only to athletes, but also to amateurs. The use of AAS may be associated with numerous complications. These include an increased risk of cardiovascular disease. The literature describes the effect of AAS use on the occurrence of dyslipidemia, insulin resistance, hypertension and metabolic syndrome. All these metabolic disorders result in increased cardiovascular risk. To prevent complications, it seems best to withdraw AAS gradually under medical supervision to minimize withdrawal effects. Conclusion: The use of AAS may cause cardiovascular disease, but additional long-term studies are needed to prove this. It is necessary to sensitize patients and doctors to the problem of AAS abuse in society, because this issue can become a significant risk factor for cardiovascular diseases in near future.
- 19 August 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 45 (1) , 269-283
Open AccessWill the use of anabolic androgenic steroids become a significant cardiovascular risk factor in the future?
Introduction and purpose: Cardiovascular diseases are the leading cause of mortality in many European countries. Major modifiable risk factors include dyslipidemia, hypertension, smoking and diabetes. The aim of our study is to draw attention to the possible impact of the use of anabolic androgenic steroids on increased cardiovascular risk. Brief description of the state of knowledge: Currently, an increasing proportion of the population uses anabolic-androgenic steroids (AAS). This situation applies not only to athletes, but also to amateurs. The use of AAS may be associated with numerous complications. These include an increased risk of cardiovascular disease. The literature describes the effect of AAS use on the occurrence of dyslipidemia, insulin resistance, hypertension and metabolic syndrome. All these metabolic disorders result in increased cardiovascular risk. To prevent complications, it seems best to withdraw AAS gradually under medical supervision to minimize withdrawal effects. Conclusion: The use of AAS may cause cardiovascular disease, but additional long-term studies are needed to prove this. It is necessary to sensitize patients and doctors to the problem of AAS abuse in society, because this issue can become a significant risk factor for cardiovascular diseases in near future.
- Open Access
- 15 August 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 44 (1) , 185-202
Energy drinks - product ingredients and their potential toxicity
Energy drinks (NE) are popular stimulants among adolescents and adults. They are commercial, advertised, widely available products that contain increased amounts of caffeine, and are designed to reduce feelings of fatigue in favor of increased mental and physical performance. In addition to caffeine, various ingredients such as vitamins, dyes or substances that impart a certain flavor are added to NEs. Many cases have been described of the harmful effects of NE used alone and in combination with alcohol on the human body: including on the digestive system, central nervous system, cardiovascular system or kidneys. We decided to analyze and compare with each other the composition of NEs from the most popular manufacturers available in most Polish grocery stores. We then briefly described the most important substances available in NE and reviewed the literature on their potential toxicity. It is reasonable for physicians and teachers to educate young people and their parents about the harmfulness of NE, especially when children are suspected of taking large amounts. Further observations and studies monitoring the harmfulness of NEs are needed, and the drinks themselves should be subject to special surveillance.
- 15 August 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 44 (1) , 185-202
Open AccessEnergy drinks - product ingredients and their potential toxicity
Energy drinks (NE) are popular stimulants among adolescents and adults. They are commercial, advertised, widely available products that contain increased amounts of caffeine, and are designed to reduce feelings of fatigue in favor of increased mental and physical performance. In addition to caffeine, various ingredients such as vitamins, dyes or substances that impart a certain flavor are added to NEs. Many cases have been described of the harmful effects of NE used alone and in combination with alcohol on the human body: including on the digestive system, central nervous system, cardiovascular system or kidneys. We decided to analyze and compare with each other the composition of NEs from the most popular manufacturers available in most Polish grocery stores. We then briefly described the most important substances available in NE and reviewed the literature on their potential toxicity. It is reasonable for physicians and teachers to educate young people and their parents about the harmfulness of NE, especially when children are suspected of taking large amounts. Further observations and studies monitoring the harmfulness of NEs are needed, and the drinks themselves should be subject to special surveillance.
- Open Access
- 27 June 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 42 (1) , 52-62
Migraine headaches as a complication of the atrial fibrillation ablation procedure: case report
The balloon cryoablation (CA) procedure is an established method for the permanent treatment of atrial fibrillation (AF). Like other surgical interventions, it is associated with the potential development of early and late complications, including neurological ones such as migraine. We report a case of migraine headaches after the CA procedure. 25-year-old man with paroxysmal AF, without comorbidities, underwent balloon CA. On the second day after the procedure, the patient developed visual symptoms typical of migraine aura. After 30 minutes, these symptoms disappeared and appeared classic migraine headache attack. Similar episodes occurred over the following days. A focal central nervous system lesion was ruled out and a diagnosis of migraine with aura was made. The patient received a typical migraine attack treatment. The attacks ceased within two weeks. 3 months later during the follow-up visit at the neurology clinic no abnormalities were detected. We decided to check if the migraine is a rare complication of AF ablation surgery. Many studies do not include migraine headaches at all in the neurological complications of ablation. However, based on some studies, it may seem that the incidence of migraine as a complication of ablation is underestimated.
- 27 June 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 42 (1) , 52-62
Open AccessMigraine headaches as a complication of the atrial fibrillation ablation procedure: case report
The balloon cryoablation (CA) procedure is an established method for the permanent treatment of atrial fibrillation (AF). Like other surgical interventions, it is associated with the potential development of early and late complications, including neurological ones such as migraine. We report a case of migraine headaches after the CA procedure. 25-year-old man with paroxysmal AF, without comorbidities, underwent balloon CA. On the second day after the procedure, the patient developed visual symptoms typical of migraine aura. After 30 minutes, these symptoms disappeared and appeared classic migraine headache attack. Similar episodes occurred over the following days. A focal central nervous system lesion was ruled out and a diagnosis of migraine with aura was made. The patient received a typical migraine attack treatment. The attacks ceased within two weeks. 3 months later during the follow-up visit at the neurology clinic no abnormalities were detected. We decided to check if the migraine is a rare complication of AF ablation surgery. Many studies do not include migraine headaches at all in the neurological complications of ablation. However, based on some studies, it may seem that the incidence of migraine as a complication of ablation is underestimated.